NEOPROBE CORP
10-Q, EX-27, 2000-11-13
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: NEOPROBE CORP, 10-Q, EX-11.1, 2000-11-13
Next: ANDOVER BANCORP INC, 10-Q, 2000-11-13



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                       3,270,861
<SECURITIES>                                         0
<RECEIVABLES>                                1,156,574
<ALLOWANCES>                                    79,820
<INVENTORY>                                    453,321
<CURRENT-ASSETS>                             4,850,869
<PP&E>                                       2,200,623
<DEPRECIATION>                               1,320,138
<TOTAL-ASSETS>                               6,502,662
<CURRENT-LIABILITIES>                        1,824,585
<BONDS>                                         35,903
                                0
                                          0
<COMMON>                                        26,264
<OTHER-SE>                                   2,215,910
<TOTAL-LIABILITY-AND-EQUITY>                 6,502,662
<SALES>                                      6,242,461
<TOTAL-REVENUES>                             6,892,461
<CGS>                                        3,512,767
<TOTAL-COSTS>                                3,512,767
<OTHER-EXPENSES>                               435,620
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              20,435
<INCOME-PRETAX>                              1,142,837
<INCOME-TAX>                                    26,296
<INCOME-CONTINUING>                          1,116,541
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,116,541
<EPS-BASIC>                                       0.01
<EPS-DILUTED>                                     0.01


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission